Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma

NATerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Esophageal Adenocarcinoma
Interventions
DRUG

Capecitabine

Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4

DRUG

Oxaliplatin

Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4

DRUG

Cetuximab

Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection

Trial Locations (1)

80045

University of Colorado at Denver and Health Science Center, Aurora

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

University of Colorado, Denver

OTHER